fl115
Recombinant proteinexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 30, 2023 (NCT06130722)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- IL15-IL15 receptorAGONIST
IL15-IL15 receptor agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07131202 | Phase 1/Phase 2 (Phase 2) | Sep 8, 2025 | Government of China |
| NCT07122414 | Phase 1/Phase 2 (Phase 2) | Aug 16, 2024 | Government of China |
| NCT07131189 | Phase 1 | May 30, 2024 | Government of China |
| NCT06130722 | Phase 1 | Oct 30, 2023 | Government of China |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 4 | 4 | 2 | 2023 |
1 organizations
Page 1 / 1